Low-dose cyclosporin therapy for recombinant erythropoietin-induced pure red-cell aplasia

Open Access
Publisher Website
Google Scholar
Abstract
Pure red-cell aplasia (PRCA) is an uncommon condition. It has been reported to occur in dialysis patients following recombinant erythropoietin therapy, initiated for treatment of anaemia of chronic renal failure [1–3]. In those patients, anti-erythropoietin antibodies have been recorded. Little is known of the natural history of this disease or the safest, most efficacious therapy. Here we describe a patient with only moderate renal impairment, who also developed epoetin-induced PRCA. Initial bone marrow histology failed to make a clear diagnosis. There was no spontaneous remission, but the patient was managed successfully with low-dose cyclosporin alone without compromising renal function.

This publication has 0 references indexed in Scilit: